Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $25.1 million.

  • Denali Therapeutics' Other Non-Current Assets fell 521.39% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 521.39%. This contributed to the annual value of $24.7 million for FY2024, which is 3636.66% up from last year.
  • As of Q3 2025, Denali Therapeutics' Other Non-Current Assets stood at $25.1 million, which was down 521.39% from $23.0 million recorded in Q2 2025.
  • Denali Therapeutics' Other Non-Current Assets' 5-year high stood at $50.6 million during Q2 2024, with a 5-year trough of $3.6 million in Q2 2021.
  • Over the past 5 years, Denali Therapeutics' median Other Non-Current Assets value was $15.2 million (recorded in 2022), while the average stood at $19.0 million.
  • In the last 5 years, Denali Therapeutics' Other Non-Current Assets soared by 38216.9% in 2021 and then tumbled by 5458.5% in 2025.
  • Denali Therapeutics' Other Non-Current Assets (Quarter) stood at $11.9 million in 2021, then rose by 12.87% to $13.4 million in 2022, then soared by 35.41% to $18.1 million in 2023, then skyrocketed by 36.37% to $24.7 million in 2024, then rose by 1.48% to $25.1 million in 2025.
  • Its Other Non-Current Assets stands at $25.1 million for Q3 2025, versus $23.0 million for Q2 2025 and $26.9 million for Q1 2025.